Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I didn't find a vampire green in the color list but I did find a zombie green. hex code #54C571
Replace the red with the #54C571 and see if that works for you.
This sentence is in zombie green.
I love new toys. 😁
Thanks for the color list
Turns out you can use the Hex color code off the list and get any of the colors.
Including my new fav Rubber Ducky Yellow as seen above.
I wonder what the BOD would consider as an acceptable price?
$1248 sh would work for me. 🤑
Good point.Test Chartreuse
Well I'll be...
Lime green and chartreuse do work. Well chartreuse sort of. I can barely read it.
I should modify my no partnership statement. My guess is Missling means no signed partnership till AD is approved.
Seems quite likely that talks are going on currently as different companies make offers and try to figure out the lay of the land.
A partnership can be configured many different ways. Each potential partner has its own specific needs in a deal so Missling has to see which ones most closely fit with Anavex's own needs and goals.
Indeed most of it was. That is part of why I am confused. The initial post I reported to Admin as OT and it was left in place.
Yeah I know, nobody's perfect and neither is a system.
When you select the color highlight for a range of text. The default is red. You can change it to other colors by replacing the red with another cover. Although Chartreuse doesn't seem to be an option.
As a mod I made a post to the stock board about cooling it with the name calling that was becoming frequent on the board. That post was deleted by Admin.
As a mod is it OT to suggest a bit more decorum? I realize the rules are in a bit of flux, I'm looking for a bit of guidance. Posts on the national debt are considered on topic on a stock specific board.
I'm confused.
Missling has made it clear no buyout. No partnership till AD is approved.
Rett approval will fund the company until AD approval. My guess is that if the company felt the need to raise additional funds after Rett approval the SP will be high enough that it won't take many shares to raise whatever Anavex decides it needs.
Very few of the posts I have referred to Admin for deletion have actually been deleted.
Turns out that anonymity doesn't bring out the best in people.
To assume that most people are willing to be nice to one another is probably not wrong but relying on that doesn't take into account the rest of the population.
When you create a school yard environment you get school yard results. There is a reason that teachers patrol the schoolyard.
When Ihub removed Mod's ability to police the school yard, childish fights and name calling broke out.
Who knew?
The post did not show the year of the quoted material. Only if you opened the link did the year become visible.
So you might consider showing a little .... Nah... never happen. Never mind.
You still have 11,000,000 shares?
All very interesting, none of which has anything to do with Anavex, the trials underway or just completed.
Like many here I am well up on my Anavex investment both monetarily and in understanding.
If you have a better place to invest high risk money then let's hear it, otherwise I'll stick with Anavex.
Wow! That's all I can say. Just Wow!
It would be nice if the company released the data and convinced the world.
I'd be happy if the company convinces the FDA.
Turns out I make mistakes sometimes when typing. Get over it.
I modeled the OR and found a ratio that matched the OR given by the company. I'd have to go back and find the post but as I recall is was about 32 treated patients met the threshold or better.
As I said the OR was illustrative. I also mentioned the issues with limited measurements yielding placebo improvers. If that information wasn't as informative as you would like well, ca ca occurs.
All in all, this doesn't matter much.
What matters is what the FDA thinks about the information that is presented in the NDA. Your opinion or mine matters not.
It does give you something to whine about on a message board so in that regard you should be grateful.
It starts by buying 11 million shares.
The concept of super responders is not that difficult.
AD is a progressive disease. It may sometimes plateau it seldom, if ever, has patients recovering lost capabilities.
The super responders actually recover lost abilities. The FDA doesn't have a category for super responders because they haven't been seen before.
True that the super responders are few in number on a percentage basis. However that small percentage is compared with zero percentage previously seen.
In trials, due to the testing infrequency and the fact that people have good days and bad days with AD, sometimes modest improvements are seen.
That is why the odds ratio statistic is interesting. It addresses the two items just referenced.
The super responders seen in the P2a trial are real world experience cases. The standard stats would not capture their extraordinary recovery of lost skills.
AFAIK there were no OR endpoints.
There was OR given in the presentation in what appeared to me to be an illustrative manner to show improvement over baseline.
What evidence do you have to support you statement that the company is struggling with getting clear dose sub-grouping?
Titration by its nature leads to a data point spread. Since titration is not uncommon there must be ways of statistically dealing with it.
Biology is messy.
You suppose wrong.
I would like complete TLR data. Turns out I don't always get what I want. I get over it.
What matters is what the FDA thinks about the trial results.
The company has repeatedly stated that the endpoints were met. If that is not the case then the company hasn't shot it self in the foot, it has shot itself in the head.
I don't think Missling would do that.
Dealing with inadequate information is a big part of investing.
There are several ways that the AD trial might not directly lead to approval. Even if the endpoints in the P2b/3 trial were met the FDA could want to see larger numbers than were in this trial. Also FDA could simply want to see a second P3 trial.
Anavex going for AA would alleviate both of those possible concerns by requiring a P3/4 trial of a size that makes the FDA happy while getting a treatment better than the current AD SOC available for patients.
Metaphor mania. Is that treatable?
Good point.
It is far more abnormal for a company to repeatedly state that it met ALL endpoints in a trial when it did not and expose the company to massive lawsuits and financial disaster.
...but it's abnormal for a company to substitute OR for comparison of means in this context and not to provide supporting statistics that address their own stated endpoint...
Actually what was said was the company met its endpoints. Which means to me that the trial met its stated endpoints.
So please educate me about the concept of "endpoint" that is so misunderstood.
I think I know the answer to that. Anavex wins by Rett.
AD is not likely a winner take all game.
Are you the leader of the pack?
The probability of approval for Rett is higher than AD. The time line for approval for Rett VS AD is pretty close to the same due to Fast Track for Rett.
It will take 6 months post approval for AD to really bring in the big revenues. Rett will not require a partner like AD will.
Rett approval will improve the chances of AD approval.
Rett voucher is an immediate value to the books. If Anavex chooses to use the voucher it can be used on AD and will speed up FDA consideration by 3 months.
If Anavex chooses to sell the voucher that is an immediate cash infusion to the company of $100 Million and possibly a bit more.
I have posed this question to the board several times and is seems relevant as a response to your post.
Where besides AVXL would you place your high risk investment money that has a better potential return?
Missling has stated that he wants the voucher which means Rett approved before AD.
That automatically makes AD a "repurposed" drug.
New testing protocol for AD. It looks for a form of tau and then has a second testing step using CSF for those in the first step that have uncertain results.
https://medicalxpress.com/news/2023-08-blood-high-accuracy-screen-alzheimer.html
I use Medved Trader to chart and LVL II. Data source is TDA. Both are free. It's all real time.
Medved is the free somewhat restricted version. I highly recommend it.
Someone or Some insty wanted AVXL 75K trade @ $7.95 printed at 15:12
Sold my $7.50 options for a small loss. Ooops. Wasn't willing to wait for tomorrow since it is a three day weekend.
And here I thought it made my point pretty well. Sorry you found it offensive.
There are more things in heaven and Earth, Horatio, / Than are dreamt of in your philosophy.
Wow. Did the A/C quit in the basement? You seem particularly testy today.
More research on AD. Interesting pathways elucidated.
https://medicalxpress.com/news/2023-08-scientists-reverse-alzheimer-plaque-formation.html
Perhaps the calm before the storm?